Literature DB >> 29573440

Do Electronic Cigarettes Have a Role in Tobacco Cessation?

Andrea S Franks1, Karen Sando2, Sarah McBane3.   

Abstract

Tobacco use continues to be a major cause of morbidity and mortality. Even with behavioral and pharmacologic treatment, long-term tobacco cessation rates are low. Electronic nicotine delivery systems, commonly referred to as electronic cigarettes or e-cigarettes, are increasingly used for tobacco cessation. Because e-cigarettes are widely used in this setting, health care professionals need to know if they are safe and effective. The purpose of this article is to review literature regarding use of e-cigarettes as a tool for tobacco cessation in patients who are ready to quit, as well as those who are not ready to quit, along with some selected patient populations. The safety and clinical implications of e-cigarette use are also reviewed. Small, short-term studies assessing smokers' use of e-cigarettes suggest that e-cigarettes may be well tolerated and modestly effective in achieving abstinence. High-quality studies are lacking to support e-cigarettes use for cessation in patients with mental health issues. One small prospective cohort study concluded that patients with mental health issues reduced cigarette use with e-cigarette use. Although one study found that patients with cancer reported using e-cigarettes as a tobacco-cessation strategy, e-cigarettes were not effective in supporting abstinence 6 and 12 months later. Additional research is needed to evaluate the use of e-cigarettes for smoking cessation in patients with pulmonary diseases. No data exist to describe the efficacy of e-cigarettes for smoking cessation in pregnant women. Although study subjects report minimal adverse effects with e-cigarettes and the incidence of adverse effects decreases over time, long-term safety data are lacking. Health care providers should assess e-cigarette use in their patients as part of the tobacco cessation process.
© 2018 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  asthma; cancer; chronic obstructive pulmonary disease; e-cigarettes; electronic nicotine delivery systems; pregnancy; tobacco cessation

Mesh:

Year:  2018        PMID: 29573440     DOI: 10.1002/phar.2103

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  4 in total

1.  Electronic Cigarette Vapor with Nicotine Causes Airway Mucociliary Dysfunction Preferentially via TRPA1 Receptors.

Authors:  Samuel Chung; Nathalie Baumlin; John S Dennis; Robert Moore; Sebastian F Salathe; Phillip L Whitney; Juan Sabater; William M Abraham; Michael D Kim; Matthias Salathe
Journal:  Am J Respir Crit Care Med       Date:  2019-11-01       Impact factor: 21.405

2.  Impact of electronic cigarette heating coil resistance on the production of reactive carbonyls, reactive oxygen species and induction of cytotoxicity in human lung cancer cells in vitro.

Authors:  Silvia Cirillo; Jose F Urena; Joshua D Lambert; Fabio Vivarelli; Donatella Canistro; Moreno Paolini; Vladimiro Cardenia; Maria Teresa Rodriguez-Estrada; John P Richie; Ryan J Elias
Journal:  Regul Toxicol Pharmacol       Date:  2019-10-17       Impact factor: 3.271

Review 3.  A narrative review evaluating the safety and efficacy of e-cigarettes as a newly marketed smoking cessation tool.

Authors:  Dominic Worku; Elliott Worku
Journal:  SAGE Open Med       Date:  2019-08-18

4.  Smoking Cessation and Vaping Cessation Attempts among Cigarette Smokers and E-Cigarette Users in Central and Eastern Europe.

Authors:  Mateusz Jankowski; Joshua Allan Lawson; Andrei Shpakou; Michał Poznański; Tadeusz Maria Zielonka; Ludmila Klimatckaia; Yelena Loginovich; Marta Rachel; Justína Gereová; Łukasz Minarowski; Ihar Naumau; Kamil Kornicki; Paulina Pepłowska; Valeriy Kovalevskiy; Asta Raskiliene; Krzysztof Bielewicz; Zuzana Krištúfková; Robert Mróz; Paulina Majek; Szymon Skoczyński; Jan Eugeniusz Zejda; Grzegorz Marek Brożek
Journal:  Int J Environ Res Public Health       Date:  2019-12-18       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.